Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA4 | P22748 | 8/20 | 0.68 |
| ▸ | CA9 | Q16790 | 8/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA3 | P07451 | 3/20 | 0.60 |
| ▸ | CA6 | P23280 | 3/20 | 0.60 |
| ▸ | CA5A | P35218 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CA11 | O75493 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9390106 | 0.82 | CA1 (0.69) | CA2CA1CA4CA9CA12 | |
| SCHEMBL11049891 | 0.81 | CA1 (1.00) | CA2CA1CA4CA9CA12 | |
| SCHEMBL9403512 | 0.80 | CA1 (0.80) | CA2CA1CA4CA9CA12 | |
| SCHEMBL19383010 | 0.80 | CA1 (0.80) | CA2CA1CA4CA9CA12 | |
| SCHEMBL19382585 | 0.79 | CA1 (0.74) | CA2CA1CA4CA9CA12 | |
| SCHEMBL308753 | 0.78 | CA1 (1.00) | CA2CA1CA4CA9CA12 | |
| Bromide SCHEMBL9403550 | 0.78 | CA1 (0.78) | CA2CA1CA4CA9CA12 | |
| Propazolamide SCHEMBL1817525 | 0.78 | CA1 (1.00) | CA2CA1CA4CA9CA12 | |
| SCHEMBL19382598 | 0.77 | CA1 (0.70) | CA2CA1CA4CA9CA12 | |
| Acetazolamide SCHEMBL2557036 | 0.76 | CA1 (1.00) | CA2CA1CA4CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264827-A1 | SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264827-A1 | SULFANYLAMIDE DERIVATIVES, USES THEREOF AND COMPOSITIONS COMPRISING THEM | CNR2, SULT2A1, CYP2S1 | CA2 1138/4885CA1 291/4885CA4 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.